Bristol Myers drug combo fails to meet main goal in kidney cancer trial
July 29 (Reuters) - Bristol Myers Squibb (BMY.N)said on Friday a trial evaluating a combination of its two cancer drugs failed to meet the primary goal to treat localized kidney cancer.
The combination of the two drugs - Yervoy and top selling cancer drug Opdivo - is already approved in the United States as a first line of treatment for patients with renal cell carcinoma that has spread.
However, the combination failed to meet the key endpoint of disease-free survival for patients who had localized form of the cancer and had undergone full or partial removal of the kidney.
Shares of Bristol Myers were down 1.1% premarket at $73.90.
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-drug-combo-fails-meet-mail-goal-kidney-cancer-trial-2022-07-29/
Ann: Zircon Kidney Cancer Imaging Study completes Enrollment, page-17
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.00 |
Change
0.070(0.35%) |
Mkt cap ! $6.692B | |||
| Open | High | Low | Value | Volume |
| $20.20 | $20.30 | $19.86 | $28.76M | 1.435M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350 | $19.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.01 | 215 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |